Literature DB >> 22350659

Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome.

J P Gonçalves1, A Oliveira, M Severo, A C Santos, C Lopes.   

Abstract

Research on the importance of serum uric acid (SUA) as a contributing metabolic factor to cardiovascular diseases has conducted to conflicting results, with most studies assuming a cross-sectional design. The aim of this study was to evaluate the association of SUA and metabolic syndrome (MetS) and its features. A representative sample of 2,485 individuals aged ≥18 years was randomly selected from the non-institutionalized resident population of Porto, Portugal. A total of 1,054 eligible subjects were included for the longitudinal analyses. Hyperuricemia was defined as SUA ≥70 mg/L in men and ≥60 mg/L in women. MetS was defined according the Joint Interim (2009) criteria. Associations were estimated using Poison regression and binomial models. In the cross-sectional analysis, subjects with hyperuricemia had a 2.10-fold increased risk of MetS as compared with normouricemic subjects (PR = 2.10, 95% CI: 1.68-2.63). Among MetS features, high triglycerides presented the strongest association with hyperuricemia (PR = 2.32, 95% CI: 1.84-2.91). The MetS crude incidence rate was 4.5/100 person-year (95% CI: 3.9-5.2) in normal uricemic and 13.0/100 person-year (95% CI: 8.5-20.0) in hyperuricemic participants. Using a multivariate longitudinal approach, hyperuricemia was positively associated with MetS incidence rate ratios (IRR = 1.73, 95% CI: 1.08-2.76). One standard deviation increase of SUA concentration was associated with a 1.22-fold increase in MetS risk (IRR = 1.22, 95% CI: 1.05-1.42). Elevated SUA presented the strongest association with high-triglycerides concentration (IRR = 1.44, 95%: 1.22-1.71) and waist circumference (IRR = 1.25, 95%: 1.05-1.49). The independent positive association between SUA and MetS suggested by this longitudinal study supports that SUA might be a risk factor for MetS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350659     DOI: 10.1007/s12020-012-9629-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  45 in total

1.  Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation.

Authors:  Kazuko Masuo; Hideki Kawaguchi; Hiroshi Mikami; Toshio Ogihara; Michael L Tuck
Journal:  Hypertension       Date:  2003-09-02       Impact factor: 10.190

2.  Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity.

Authors:  Kevin J Cheung; Iphigenia Tzameli; Pavlos Pissios; Ilsa Rovira; Oksana Gavrilova; Toshio Ohtsubo; Zhu Chen; Toren Finkel; Jeffrey S Flier; Jeffrey M Friedman
Journal:  Cell Metab       Date:  2007-02       Impact factor: 27.287

3.  Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done?

Authors:  M L Thompson; J E Myers; D Kriebel
Journal:  Occup Environ Med       Date:  1998-04       Impact factor: 4.402

4.  The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates.

Authors:  F Cardona; F J Tinahones; E Collantes; A Escudero; E García-Fuentes; F J Soriguer
Journal:  Rheumatology (Oxford)       Date:  2003-03       Impact factor: 7.580

5.  The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study.

Authors:  A Shankar; R Klein; B E K Klein; F J Nieto
Journal:  J Hum Hypertens       Date:  2006-10-05       Impact factor: 3.012

6.  Odds ratio or relative risk for cross-sectional data?

Authors:  J Lee
Journal:  Int J Epidemiol       Date:  1994-02       Impact factor: 7.196

7.  Relationship between hyperuricemia and metabolic syndrome.

Authors:  Li-ying Chen; Wen-hua Zhu; Zhou-wen Chen; Hong-lei Dai; Jing-jing Ren; Jian-hua Chen; Lei-qian Chen; Li-zheng Fang
Journal:  J Zhejiang Univ Sci B       Date:  2007-08       Impact factor: 3.066

8.  Lifestyle factors and incident metabolic syndrome. The Tromsø Study 1979-2001.

Authors:  Tom Wilsgaard; Bjarne K Jacobsen
Journal:  Diabetes Res Clin Pract       Date:  2007-04-19       Impact factor: 5.602

Review 9.  Uric acid: role in cardiovascular disease and effects of losartan.

Authors:  Michael Alderman; Kala J V Aiyer
Journal:  Curr Med Res Opin       Date:  2004-03       Impact factor: 2.580

Review 10.  The conundrum of hyperuricemia, metabolic syndrome, and renal disease.

Authors:  Takahiko Nakagawa; Pietro Cirillo; Waichi Sato; Michael Gersch; Yuri Sautin; Carlos Roncal; Wei Mu; L Gabriela Sánchez-Lozada; Richard J Johnson
Journal:  Intern Emerg Med       Date:  2008-03-05       Impact factor: 3.397

View more
  42 in total

1.  Gender impact on the correlations between subclinical thyroid dysfunction and hyperuricemia in Chinese.

Authors:  Jianping Zhang; Zhaowei Meng; Qing Zhang; Li Liu; Kun Song; Jian Tan; Xue Li; Qiang Jia; Guizhi Zhang; Yajing He
Journal:  Clin Rheumatol       Date:  2015-01-21       Impact factor: 2.980

2.  The Power of Serum Uric Acid in Predicting Metabolic Syndrome Diminishes With Age in an Elderly Chinese Population.

Authors:  J-H Chen; C-H Hsieh; J-S Liu; T-J Chuang; H-W Chang; C-L Huang; P-F Li; D Pei; Y-L Chen
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

3.  The Role of Uric Acid for Predicting Future Metabolic Syndrome and Type 2 Diabetes in Older People.

Authors:  J-B Chang; Y-L Chen; Y-J Hung; C-H Hsieh; C-H Lee; D Pei; J-D Lin; C-Z Wu; Y-J Liang; C-M Lin
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

4.  Baseline and changes in serum uric acid independently predict 11-year incidence of metabolic syndrome among community-dwelling women.

Authors:  R Kawamoto; D Ninomiya; Y Kasai; K Senzaki; T Kusunoki; N Ohtsuka; T Kumagi
Journal:  J Endocrinol Invest       Date:  2018-02-19       Impact factor: 4.256

5.  Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study.

Authors:  Yoshitaka Hashimoto; Muhei Tanaka; Toshihiro Kimura; Noriyuki Kitagawa; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Yohei Oda; Hitoshi Toda; Naoto Nakamura; Michiaki Fukui
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

6.  Elevated uric acid, the metabolic syndrome and cardiovascular disease: cause, consequence, or just a not so innocent bystander?

Authors:  Raul D Santos
Journal:  Endocrine       Date:  2012-03-27       Impact factor: 3.633

Review 7.  Hyperuricemia and cardiovascular risk.

Authors:  Davide Grassi; Giovambattista Desideri; Anna Vittoria Di Giacomantonio; Paolo Di Giosia; Claudio Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-02-20

8.  Is lower uric acid level better? A combined cross-sectional and longitudinal study in the elderly.

Authors:  Chang-Hsun Hsieh; Jiunn-Diann Lin; Chung-Ze Wu; Chun-Hsien Hsu; Dee Pei; Yao-Jen Liang; Yen-Lin Chen
Journal:  Endocrine       Date:  2014-02-21       Impact factor: 3.633

9.  Association of hematological parameters with metabolic syndrome in Beijing adult population: a longitudinal study.

Authors:  Li-Xin Tao; Xia Li; Hui-Ping Zhu; Da Huo; Tao Zhou; Lei Pan; Yan-Xia Luo; Wei Wang; Zhao-Ping Wang; Dong-Ning Chen; Li-Juan Wu; Xiu-Hua Guo
Journal:  Endocrine       Date:  2013-10-04       Impact factor: 3.633

10.  Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population.

Authors:  Eiji Oda
Journal:  Heart Vessels       Date:  2013-06-28       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.